Latest updates on chronic viral hepatitis B
MARMARA MEDICAL JOURNAL, cilt.29, ss.33-37, 2016 (ESCI, Scopus, TRDizin)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 29
- Basım Tarihi: 2016
- Doi Numarası: 10.5472/mmjsi.2901.07
- Dergi Adı: MARMARA MEDICAL JOURNAL
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.33-37
- Anahtar Kelimeler: Chronic hepatitis B, Nucleos(t)ide analog, Entecavir, Tenofovir disoproxil fumarate
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Ankara Üniversitesi Adresli: Evet
Özet
Hepatitis B virus (HBV) remains a major cause of liver-related morbidity and mortality in Turkey and all over the world. Two different types of antiviral agents can be used in the treatment of chronic hepatitis B (CHB). Conventional (IFN) or pegylated interferon alpha (PegIFN), nucleoside [lamivudine (LMV), telbivudine, emtricitabine, entecavir (ETV)] and nucleotide analogs [adefovir dipivoxil (ADV)] and tenofovir disoproxil fumarate (TDF)]. Antiviral agent must ensure a degree of HBV viral suppression and will lead to biochemical, serological remission and histological improvement. Current treatment strategies are discussed in present brief report.